Compounds

1. A compound of formula (I):

wherein

R 1 represents hydrogen, hydroxyl, C 1 -C 6 alkoxy, C 2 -C 5 alkoxycarbonyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, or a C 6 -C 10 aryl, C 5 -C 10 heteroaryl or C 3 -C 8 cycloalkyl group, each group being optionally substituted by one or more substituents independently selected from halogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 2 -C 5 alkoxycarbonyl, amino (NH 2 ) and di-C 1 -C 6 alkylamino;

Y 1 represents a single bond or C 1 -C 6 alkylene;

X 1 represents a single bond or an oxygen or sulphur atom or sulphonyl (SO 2 ) or NR 3 ;

Z 1 represents a C 2 -C 6 alkylene or C 3 -C s cycloalkylene group, each of which may be optionally substituted by at least one hydroxyl;

X 2 represents NR 4 , CONR 4 , NR 4 CO, SO 2 NR 4 , NR 4 CONR 5 , NR 5 CONR 4 , SO 2 , CO or NR 5 CSNR 5 ;

Y 2 represents a single bond or C 1 -C 6 alkylene;

n is 0, 1 or 2;

each R 2 group independently represents halogen, cyano, S(O) m R 9 , OR 10 , SO 2 NR 10 R 11 , CONR 10 R 11 , NR 7 R 8 , NR 10 SO 2 R 9 , NR 10 CO 2 R 9 , NR 10 COR 9 , C 6 -C 10 aryl, C 5 -C 10 heteroaryl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 8 cycloalkyl group, the latter six groups being optionally substituted by one or more substituents independently selected from halogen, cyano, S(O) m R 12 , OR 13 , SO 2 NR 13 R 14 , CONR 13 R 14 , NR 7 R 8 , NR 13 SO 2 R 12 , NR 13 CO 2 R 12 , NR 13 COR 12 , C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl;

R 3 represents hydrogen or C 1 -C 6 alkyl;

R 4 represents hydrogen or a 3- to 8-membered saturated heterocyclic ring comprising a ring group O or NR 6 , or R 4 represents a C 1 -C 6 alkylene optionally substituted by one or more substituents independently selected from NR 7 R 8 or R 6 ;

R 5 represents hydrogen or a C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen, hydroxyl and NR 7 R 8 ;

R 6 represents hydrogen, CO 2 R 9 , SO 2 R 9 , COR 9 , SO 2 NR 10 R 11 , CONR 10 R 11 , a 3- to 8-membered saturated heterocyclic ring comprising a ring group NR 9 , or

(i) a C 6 -C 10 aryl or C 5 -C 10 heteroaryl group, each of which may be optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, carboxyl, S(O) m R 12 , OR 13 , SO 2 NR 13 R 14 , CONR 13 R 14 , NR 13 R 14 , NR 13 SO 2 R 12 , NR 13 CO 2 R 12 , NR 13 COR 12 , C 1 -C 6 alkyl and C 1 -C 3 haloalkyl, or

(ii) a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 8 cycloalkyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen, cyano, C 3 -C 8 cycloalkyl, OR 15 , S(O) p R 16 , CO 2 R 16 , NR 17 R 18 , CONR 17 , R 18 , NR 17 COR 16 , SO 2 NR 17 R 18 , NR 17 SO 2 R 16 and substituents defined in (i) above;

R 7 , R 8 , R 13 , R 14 , R 15 , R 19 , R 20 , R 22 , R 23 , R 24 and R 25 each independently represent hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl; or

R 7 and R 8 together with the nitrogen atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring comprising a ring nitrogen atom and optionally one or more further heteroatoms independently selected from nitrogen, oxygen, sulphur and sulphonyl, the heterocyclic ring being optionally substituted by one or more substituents independently selected from halogen, hydroxyl, carboxyl, cyano, OR 21 , S(O) q R 21 , NR 22 R 23 , C 1 -C 6 alkyl and C 3 -C 8 cycloalkyl;

R 9 , R 16 and R 21 each independently represent a C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen, carboxyl, hydroxyl and NR 19 R 20 ;

either R 10 represents hydrogen or a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 8 cycloalkyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen, hydroxyl, carboxyl, cyano, OR 21 , S(O) q R 21 , NR 22 R 23 and C 3 -C 8 cycloalkyl, and

R 11 represents hydrogen or a C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen, hydroxyl and NR 24 R 25 ; or

R 10 and R 11 together with the nitrogen atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring comprising at least one heteroatom or heterogroup selected from nitrogen, oxygen, sulphur and sulphonyl, the heterocyclic ring being optionally substituted by one or more substituents independently selected from halogen, hydroxyl, carboxyl, cyano, OR 21 , S(O) q R 21 , NR 22 R 23 , C 1 -C 6 alkyl and C 3 -C 8 cycloalkyl;

R 12 represents C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl;

R 17 and R 18 are defined as for R 10 and R 11 respectively;

m, p and q each independently represent 0, 1 or 2; and

A represents a monocyclic or bicyclic C 6 -C 10 aryl or a monocyclic or bicyclic C 5 -C 12 heteroaryl group containing 1-3 heteroatoms;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 wherein X 1 represents oxygen, or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 wherein R 1 represents hydrogen, or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 wherein Y 1 represents C 1 -C 6 alkylene, or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 wherein Z 1 is C 2 -C 6 alkylene, or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 wherein X 2 represents N—R 4 , or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1 wherein Y 2 represents C 1 -C 6 alkylene, or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1 wherein A represents phenyl, or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 1 selected from:

6-Amino-9-{3-[benzyl(3-morpholin-4-ylpropyl)amino]propyl}-2-butoxy-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[(4-isopropoxybenzyl)(3-morpholin-4-ylpropyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[(4-methoxybenzyl)(3-morpholin-4-ylpropyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)(3-morpholin-4-ylpropyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[(3,4-dimethoxybenzyl)(3-morpholin-4-ylpropyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[(4-morpholin-4-ylbenzyl)(3-morpholin-4-ylpropyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[(3-morpholin-4-ylpropyl)(4-pyrimidin-2-ylbenzyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[[4-(methylthio)benzyl](3-morpholin-4-ylpropyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-(3-{(3-morpholin-4-ylpropyl)[(2-oxo-2H-chromen-6-yl)methyl]amino}propyl)-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-(3-{(3-morpholin-4-ylpropyl)[(2-oxo-2,3-dihydro-1,3-benzothiazol-6-yl)methyl]amino}propyl)-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[(3-morpholin-4-ylpropyl)(4-propoxybenzyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[(3,5-dimethoxybenzyl)(3-morpholin-4-ylpropyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[(2,4-dimethoxybenzyl)(3-morpholin-4-ylpropyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

(4-{[[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl] (3-morpholin-4-ylpropyl)amino]methyl}phenoxy)acetonitrile;

6-Amino-2-butoxy-9-{3-[(3-morpholin-4-ylpropyl)(4-pyrrolidin-1-ylbenzyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-(3-[(3-morpholin-4-ylpropyl)[4-(1H-1,2,4-triazol-1-yl)benzyl]amino 1 propyl)-7,9-dihydro-8H-purin-8-one;

6-Amino-2-butoxy-9-{3-[[4-(methylsulfonyl)benzyl] (3-morpholin-4-ylpropyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

4-{[[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl] (3-morpholin-4-ylpropyl)amino]methyl}-N-(tert-butyl)benzenesulfonamide;

6-Amino-2-butoxy-9-{3-[[4-(hydroxymethyl)benzyl] (3-morpholin-4-ylpropyl)amino]propyl}-7,9-dihydro-8H-purin-8-one;

6-Amino-9-(3-{benzyl[2-(dimethylamino)ethyl]amino}propyl)-2-butoxy-7,9-dihydro-8H-purin-8-one; and

6-Amino-9-{3-[benzyl(1-methylpiperidin-4-yl)amino]propyl}-2-butoxy-7,9-dihydro-8H-purin-8-one,

and pharmaceutically acceptable salts thereof.

10. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. A process for the preparation of a pharmaceutical composition as claimed in claim 9 comprising mixing the compound or a pharmaceutically acceptable salt thereof with the pharmaceutically acceptable adjuvant, diluent or carrier.

12. A pharmaceutical product comprising, in combination, two or more active ingredients including a first active ingredient which is a compound of formula (I) as defined in claim 1 , and a second active ingredient which is selected from: a phosphodiesterase inhibitor, a β2 adrenoceptor agonist, a modulator of chemokine receptor function, an inhibitor of kinase function, a protease inhibitor, a glucocorticoid, an anticholinergic agent and a non-steroidal glucocorticoid receptor agonist.